Stephen B. Hanauer*, Miles Sparrow

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


COLAL-PRED (prednisolone sodium metasulfobenzoate), which is targeted to the colon by COLAL colonic drug delivery technology, is being developed by Alizyme for the potential treatment of inflammatory bowel disease. Alizyme expect to initiate a phase III trial in 2005.

Original languageEnglish (US)
Pages (from-to)1192-1197
Number of pages6
JournalCurrent Opinion in Investigational Drugs
Issue number11
StatePublished - Nov 1 2004

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'COLAL-PRED Alizyme'. Together they form a unique fingerprint.

Cite this